These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 70187)

  • 21. Inosiplex for SSPE.
    Chalmers TC; Smith H
    Lancet; 1982 Jun; 1(8287):1475. PubMed ID: 6177984
    [No Abstract]   [Full Text] [Related]  

  • 22. The influence of inosiplex treatment on the neurological disability of patients with subacute sclerosing panencephalitis.
    DuRant RH; Dyken PR; Swift AV
    J Pediatr; 1982 Aug; 101(2):288-93. PubMed ID: 6178812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Subacute sclerosing panencephalitis: serial CT studies and magnetic resonance imaging].
    Inada H; Hattori H; Nakajima S; Iwamura C; Tanaka A; Kim M; Matsuoka O; Murata R; Inoue Y
    No To Hattatsu; 1986 May; 18(3):199-206. PubMed ID: 2423102
    [No Abstract]   [Full Text] [Related]  

  • 24. The interferon system in subacute sclerosing panencephalitis and its response to isoprinosine.
    Gadoth N; Kott E; Levin S; Hahn T
    Brain Dev; 1989; 11(5):308-12. PubMed ID: 2479277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation of the results of the treatment of patients with subacute sclerosing panencephalitis with TFX-Polfa].
    Vainiene M; Sobczyk W
    Neurol Neurochir Pol; 1985; 19(4):286-90. PubMed ID: 2419779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alpha-interferon and isoprinosine in adult-onset subacute sclerosing panencephalitis.
    Gokcil Z; Odabasi Z; Demirkaya S; Eroglu E; Vural O
    J Neurol Sci; 1999 Jan; 162(1):62-4. PubMed ID: 10064170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of subacute sclerosing panencephalitis: an overview.
    Taylor WJ; DuRant RH; Dyken PR
    Drug Intell Clin Pharm; 1984 May; 18(5):375-81. PubMed ID: 6202474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inosiplex therapy in subacute sclerosing panencephalitis. A multicentre, non-randomised study in 98 patients.
    Jones CE; Dyken PR; Huttenlocher PR; Jabbour JT; Maxwell KW
    Lancet; 1982 May; 1(8280):1034-7. PubMed ID: 6176821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of a patient with SSPE].
    Goetz O; Peller P
    Monatsschr Kinderheilkd (1902); 1980 May; 128(5):246-7. PubMed ID: 6158679
    [No Abstract]   [Full Text] [Related]  

  • 30. [Antiviral treatment of subacute sclerosing panencephalitis].
    Sobczyk W; Kulczycki J
    Neurol Neurochir Pol; 1981; 15(2):143-8. PubMed ID: 6167886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subacute sclerosing panencephalitis: influence of the clinical course and treatment with isoprinosine on non-specific cell-mediated and humoral immunity.
    Vainiene M; Członkowska A; Korlak J
    Acta Neurol Scand; 1983 May; 67(5):275-84. PubMed ID: 6192674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progressive CT abnormalities despite clinical improvement in SSPE treated with inosiplex.
    Noetzel MJ; Dodson WE
    Ann Neurol; 1983 Apr; 13(4):457-60. PubMed ID: 6188412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Assessment of early treatment results with antineoplaston AS2-1 in subacute sclerosing panencephalitis].
    Sobczyk W; Piłkowska E; Iwińska-Buksowicz B; Jakubowska T
    Neurol Neurochir Pol; 1997; 31(6):1147-56. PubMed ID: 9591301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SSPE, measles virus, and the matrix protein: report of a case with unusual immunochemical findings.
    Mandelbaum DE; Hall WW; Paneth N; Wolff RR; DeVivo DC
    Ann Neurol; 1981 Oct; 10(4):351-4. PubMed ID: 6172078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term follow-up of patients with adult-onset subacute sclerosing panencephalitis.
    Eroglu E; Gokcil Z; Bek S; Ulas UH; Ozdag MF; Odabasi Z
    J Neurol Sci; 2008 Dec; 275(1-2):113-6. PubMed ID: 18783800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymphocyte subsets, TNF alpha and interleukin-4 levels in treated and untreated subacute sclerosing panencephalitis patients.
    Anlar B; Guven A; Köse G; Okur H; Kose O; Aydin OF; Kabakus N; Altunbasak S; Herguner O; Sonmez M; Serdaroglu A
    J Neuroimmunol; 2005 Jun; 163(1-2):195-8. PubMed ID: 15885323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical effects of MND-19 (Inosiplex) on subacute sclerosing panencephalitis--a multi-institutional collaborative study--The Inosiplex-SSPE Research Committee.
    Fukuyama Y; Nihei K; Matsumoto S; Ebina T; Kamoshita S; Sato T; Arima M; Yabuuchi H; Ueda S; Ohtahara S
    Brain Dev; 1987; 9(3):270-82. PubMed ID: 2444125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined oral isoprinosine-intraventricular alpha-interferon therapy for subacute sclerosing panencephalitis.
    Gascon G; Yamani S; Crowell J; Stigsby B; Nester M; Kanaan I; Jallu A
    Brain Dev; 1993; 15(5):346-55. PubMed ID: 7506498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapeutic experiences with the immunostimulator inosine pranobex].
    Darlath W; Wybran J
    Fortschr Med; 1984 Oct; 102(37):932-4. PubMed ID: 6209193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SSPE and interferon.
    Philippart M
    Brain Dev; 1994; 16(2):168. PubMed ID: 7519415
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.